Menu
The Goodman Institute Health Blog
  • Home
  • Authors
    • Devon Herrick, Ph.D.
    • John C. Goodman
  • Popular Topics
    • Artificial Intelligence and Healthcare
    • Consumer-Driven Health Care
      • Affordable Care Act
      • Cost of Healthcare
      • COVID-19 and Public Health
      • Doctors & Hospitals
      • Public Insurance
      • Policy & Legislation
    • Direct Primary Care
    • Health Economics & Costs
      • Drug Prices & Regulations
      • Health Insurance
      • Health Reform
    • Medical Tourism
    • Telemedicine
    • Medicare
      • Single-Payer/Medicare-for-All
  • Goodman Institute
  • Contact
  • Search
The Goodman Institute Health Blog

Category: Consumer-Driven Health Care

Article on Health Care Prices Goes Off the Rails

Posted on January 10, 2023 by Devon Herrick

Have you ever noticed that liberal news outlets can trip over the facts and fail to see their relevance? Even in the rare event they stumble onto relevant facts they draw the wrong conclusions. CNBC just discovered (nearly 60 years after economists warned of the danger) that health insurance may have resulted in higher heath care prices. In the article, “How health insurance may have made health care more expensive,” the reporter quotes a variety of health policy analysts. Dr. Kongstvedt, an expert she interviewed, gave her all the information she needs to know.

+

Saturday Links

Posted on January 7, 2023January 6, 2023 by John C. Goodman
  • Dr. Marty Makary: devastating critique of NIH and Fauci.
  • How Twitter rigged the Covid debate.
  • David Henderson solution for the Southwest airlines debacle: Let foreign carriers compete in our domestic market.
  • Can you actually eat a discarded Christmas tree?
  • No tailgating at the national College Football championship game?  This is College Football’s answer to Ebeneezer Scrooge.
+

New Drug for Obesity May Become Biggest Selling Drug of All Time

Posted on January 6, 2023 by Devon Herrick

A new drug by Eli Lilly is poised to become the biggest selling drug of all time. However, a writer at NBC News is worried about whether Americans can afford it. The drug tirzepatide has completed its final stages of testing and the U.S. Food and Drug Administration is likely to approve it for weight loss in 2023. Tirzepatide is the third drug from a new class of diabetes drugs called GLP-1 agonists, which includes the drugs Wegovy and Saxenda.

+

Health Plans Now Required to Provide Price Comparison Tools and Transparency

Posted on January 6, 2023 by Devon Herrick

As of January 1st insurers and health plans are required to provide online tools to help enrollees estimate the cost of common medical services and procedures. As an aside, a future iteration of the law should also discourage medical professionals who work in hospitals or large practices controlled by private equity from only referring inside their systems without giving patients an opportunity to use the tools to shop elsewhere. I’ve never had a problem with doctors steering me to hospital-based services. Yet, I’ve heard horror stories about doctors being compensated or punish based on so-called keepage and leakage. This from Kaiser Health News:

+
  • Previous
  • 1
  • …
  • 419
  • 420
  • 421
  • 422
  • 423
  • 424
  • 425
  • …
  • 515
  • Next

For many years, our health care blog was the only free enterprise health policy blog on the internet. Then, when the NCPA closed its doors, the health blog stopped as well.

During this five-year hiatus no one else has come forward to claim the space. So, my colleagues and I have decided to restart the blog in connection with the Goodman Institute. We invite you and others to use this forum to share your views.

John C. Goodman,

Visit www.goodmaninstitute.org

Subscribe via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 42 other subscribers

Popular Topics

©2026 The Goodman Institute Health Blog | Website by Lexicom